Safety and Efficacy of SBRT in the Reirradiation for Ultra-central Thoracic Malignant Tumors

Recruiting Observational Study
Stereotactic Body Radiation Therapy Irradiation; Reaction Thoracic Tumor Recurrent Cancer
No Study Drug Researchers observe your health over time — no experimental treatment is given.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 – 80
Sex
Any
Study type
Observational
Participants needed
40 (estimated)
Sponsor
Peking University Third Hospital · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
The reirradiation of thoracic tumor is difficult. The possibility of surgery or re course radiotherapy is very small. In the NCCN guideline, only systemic treatment is recommended. However, the effective rate of systemic treatment is low. SBRT has the characteristics of high dose in tumor target area and low dose in surrounding normal tissues. In theory, SBRT is more conducive to the protection of…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * Pathological diagnosis is malignant tumor. * The location of the target lesion belongs to the ultra-central type of chest. * The target lesion had a history of radiotherapy, and the lesion diameter is ≤ 5cm. * There is no extensive systemic metastasis or although there is meta…
Contacts

Zhe Ji, M.D.

008618710002823

aschoff@163.com

CONTACT

Junjie Wang, M.D.

008601082265921

junjiewang_edu@sina.cn

CONTACT